NuCana PLC (NCNA) Live Share Price, Invest From India

NuCana PLC Stock Performance

as on June 13, 2026 at 2:16 pm IST

Day's Low
Day's High
$1.90
Day's Price Range
$2.20
$1.95
2.56%
Downside
12.82%
Upside
52 Week's Low
52 Week's High
$1.33
52-Week Price Range
$33.62
$1.95
31.79%
Downside
1624.10%
Upside

NuCana PLC share price movements today

Previous Close: $1.99
Open: $2.10
Volume: 1.8M
Day's Low - High: $1.90 - $2.20
52 Week Low - High: $1.33 - $33.62

NuCana PLC Historical Returns

1 Month Return: + 6.99 %
3 Month Return: 0 %
1 Year Return: -93.45 %
3 Year Return: -99.95 %
5 Year Return: -99.99 %

NuCana PLC Stock Fundamentals & Key Indicators

Check NuCana PLC market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$8.2M

EPS (TTM)

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0.01

Industry PE ratio

-3.486441717791411

PEG Ratio

EBITDA

-20.6M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-193.87%

NuCana PLC Stock Valuation

Track how NuCana PLC P/E has moved over time to understand its valuation trends.

NuCana PLC in the last 5 years

Overview
Trends

Lowest (-174.49x)

December 31, 2021

Industry (-3.49x)

June 12, 2026

Today (0.01x)

June 12, 2026

Highest (-0.07x)

September 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 0.01x

NuCana PLC vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of NuCana PLC with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
NuCana PLC	BUY	$8.2M	-99.99%	0.01	0.00%	NA
Alnylam Pharmaceuticals Inc	BUY	$39.7B	75.37%	74.61	12.55%	NA
Vertex Pharmaceuticals Inc	BUY	$113.1B	130.57%	26.46	35.51%	NA
Regeneron Pharmaceuticals Inc	BUY	$64.6B	16.35%	15.04	29.65%	0.59%

Stock Returns calculator for NuCana PLC Stock including INR - Dollar returns

The NuCana PLC stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

NuCana PLC investment value today

Current value as on today

₹7,106

Returns

-₹92,894

(-92.89%)

Returns from NuCana PLC Stock

-₹93,586 (-93.59%)

Dollar Impact

₹692 (+0.69%)

Analyst Recommendation on NuCana PLC Stock

Based on 10 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 10 analysts, 80% of analysts recommend a 'BUY' rating for NuCana PLC. Average target price of $104

NuCana PLC Share Price Target

Get share price movements and forecasts by analysts on NuCana PLC.

What analysts predicted

98.13%UPSIDE

Target Price

$104

Current Price

$1.95

Analyzed by

10 Analysts

Target

$104.00

NuCana PLC target price $104, a slight upside of 98.13% compared to current price of $1.95. According to 10 analysts rating.

Indian Investors' Interest in NuCana PLC Stock

Search interest for NuCana PLC Stock has decreased by -5% in the last 30 days, reflecting a downward trend in search activity.

Time period: May 16, 2026 to June 15, 2026

Change:-5% versus previous 30 day period

NuCana PLC Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	0	0
Operating Income	-9	-8	-8	-5	0	-2	-11	0	-2	-4
EBITDA	-8	-8	-8	-4	-1	-2	-11	-3	-2	-4
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-8	-8	-8	-5	0	-2	-24	0	-2	-4
Income Tax Expense	-1	-1	-1	0	0	0	0	0	0	0
Net Income	-9	-8	-8	-5	0	-3	-24	0	-2	-3
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

NuCana PLC Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	0	-	-	-	-	-	-	-	-
Gross Profit	-	0	-	-	-	-	-	-	-	0
Operating Income	-8	-22	-22	-26	-32	-45	-43	-32	-22	-20
EBITDA	-8	-22	-24	-23	-28	-41	-52	-31	-22	-20
Interest Expense	-	-	-	0	6	4	9	1	-	0
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	-8	-25	-18	-25	-36	-47	-38	-32	-22	-30
Income Tax Expense	-2	-2	-4	-4	-5	-7	-6	-4	-3	-1
Net Income	-7	-30	-17	-28	-41	-53	-38	-34	-24	-29
Net Profit Margin	0.00%	-8157.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

NuCana PLC Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-6	-6	-4	0	-2	-24	0	-2	-3
Operating Cash Flow	-5	-1	-4	-7	-3	-4	1	0	-3
Investing Cash Flow	0	0	0	0	0	0	0	0	0
Financing Cash Flow	1	0	4	2	0	9	15	0	0
Change in Cash	-4	-1	0	-4	-2	4	16	-1	-3

NuCana PLC Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-23	-13	-21	-30	-40	-32	-27	-18	-28
Operating Cash Flow	-8	-12	-23	-21	-23	-23	-26	-19	-6
Investing Cash Flow	0	0	0	-1	-3	0	2	0	0
Financing Cash Flow	77	0	0	61	0	0	0	8	24
Change in Cash	66	-9	-25	35	-27	-18	-24	-10	17

Global Institutional Holdings in NuCana PLC

Funds	Holdings
Susquehanna International Group, LLP	0%
Acadian Asset Management LLC	0%
Tower Research Capital LLC	0%
Citigroup Inc	0%
Virtu Financial LLC	0.32%

See all

Insights on NuCana PLC

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 15.5% return, outperforming this stock by 106.8%
NO EFFECT
Against Peers
In the last 3 years, NuCana plc American Depositary Share has experienced a drawdown of -99.9%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 79.2%
NEGATIVE IMPACT
Price Dip
In the last 1 year, NCNA stock has moved down by -91.3%

About NuCana PLC

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

Organisation	NuCana PLC
Headquarters	3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT
Industry	Biotechnology
CEO	Mr. Hugh Stephen Griffith
E-voting on shares	Click here to vote

Key Management of NuCana PLC

Name	Title
Mr. Ian Webster	Interim Chief Financial Officer
Prof. David Harrison	Head of Translational Medicine & Studies
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.	Chief Medical Officer
Ms. Theresa Bruce	Chief Operating Officer
Mr. Gordon Kennovin	Senior VP of CMC & Development
Dr. Stuart Grant	Senior Vice President of Regulatory Affairs
Mr. Martin Alexander Quinn	Company Secretary
Mr. Hugh Stephen Griffith	Founder, CEO & Executive Director

FAQs

What is NuCana PLC share price today?

NuCana PLC share price today is $1.95 as on June 13, 2026 at 8:46 am IST at the close of the market. NuCana PLC share today touched a day high of $2.2 and a low of $1.9.

What is the 52 week high and 52 week low for NuCana PLC share?

NuCana PLC share touched a 52 week high of $33.62 on June 12, 2025 and a 52 week low of $1.33 on March 30, 2026. NuCana PLC stock price today i.e. June 13, 2026 at 8:46 am IST is closed at $1.95,which is 94.20% down from its 52 week high and 46.62% up from its 52 week low.

What is NuCana PLC's market capitalisation today?

NuCana PLC market capitalisation is $0.00T as on June 13, 2026 at 8:46 am IST.

How to invest in NuCana PLC Stock (NCNA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for NuCana PLC on INDmoney app. Click on Buy button. You can invest as low as $1.5 in NuCana PLC Shares that will get you 0.7692 shares as per NuCana PLC share price of $1.95 per share as on June 13, 2026 at 8:46 am IST.

What is the minimum amount required to buy NuCana PLC Stock (NCNA) from India?

Indian investors can start investing in NuCana PLC (NCNA) shares with as little as ₹95.1 or $1 (as of June 15, 2026 at 2:02 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹951.00 in NuCana PLC stock (as per the Rupee-Dollar exchange rate as on June 15, 2026 at 2:02 am IST). Based on NuCana PLC share’s latest price of $1.95 as on June 13, 2026 at 8:46 am IST, you will get 5.1282 shares of NuCana PLC. Learn more about fractional shares .

What are the returns that NuCana PLC has given to Indian investors in the last 5 years?

NuCana PLC stock has given -99.99% share price returns and 30.85% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?